1. Home
  2. BGSF vs BYSI Comparison

BGSF vs BYSI Comparison

Compare BGSF & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BGSF Inc.

BGSF

BGSF Inc.

HOLD

Current Price

$5.62

Market Cap

64.0M

ML Signal

HOLD

Logo BeyondSpring Inc.

BYSI

BeyondSpring Inc.

N/A

Current Price

$1.21

Market Cap

58.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BGSF
BYSI
Founded
2007
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
64.0M
58.4M
IPO Year
2013
2016

Fundamental Metrics

Financial Performance
Metric
BGSF
BYSI
Price
$5.62
$1.21
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
6.5K
25.7K
Earning Date
05-06-2026
05-13-2026
Dividend Yield
36.04%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$93,310,000.00
N/A
Revenue This Year
$4.67
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.26
$1.16
52 Week High
$8.20
$2.44

Technical Indicators

Market Signals
Indicator
BGSF
BYSI
Relative Strength Index (RSI) 52.43 26.58
Support Level $5.49 N/A
Resistance Level $5.79 $1.60
Average True Range (ATR) 0.14 0.13
MACD -0.02 -0.04
Stochastic Oscillator 43.49 1.91

Price Performance

Historical Comparison
BGSF
BYSI

About BGSF BGSF Inc.

BGSF Inc is a national provider of consulting, managed services, and professional workforce solutions. The company operates in one segment of Property Management, which includes centralized support services through executive, marketing, human resources, information technology, accounting, treasury, and billing operations.

About BYSI BeyondSpring Inc.

BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.

Share on Social Networks: